BioNTech SE announced that the FDA lifted the partial clinical hold on its Phase 3 trial for BNT316, previously reported on October 18, 2024, allowing patient enrollment to resume for squamous non-small cell lung cancer.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.